# A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants

> **NCT02955953** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 127 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY2963016

## Key facts

- **NCT ID:** NCT02955953
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-14
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-01-04
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955953, "A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02955953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*